Hatem Hamdy Abdel Azim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hatem Hamdy Abdel Azim has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Fedro Alessandro Peccatori
Gynecologic Oncology Department European Institute of Oncology IRCCS Milan Italy
10 shared publications - Evandro de Azambuja
Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium
7 shared publications - Christos Sotiriou
Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium
3 shared publications - Sherene Loi
Division of Cancer Research Peter MacCallum Cancer Centre Melbourne Victoria Australia
3 shared publications Dominique Agbor-Tarh
Frontier Science, Kincraig, Kingussie, Scotland
2 shared publicationsGiancarlo Pruneri
Division of Pathology, European Institute of Oncology, Milan, Italy; University of Milan, School of Medicine, Milan, Italy
2 shared publications
Latest Publications
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 604
Regional nodal irradiation after breast conserving surgery for HER2-positive breast cancer: Results of a sub analysis from the ALTTO trial.
604 Background: The optimal treatment of regional nodal areas following breast-conserving surgery (BCS) is a source of debate. Two randomized trials recently demonstrated that regional nodal irradiation (RNI) can reduce the risk of recurrence in early breast cancer; however,these trials were conducted in the pre-trastuzumab era.Whether these results are applicable to HER2-positive breast cancer patients treated with anti-HER2 targeted therapy, is unknown. Methods: This retrospective analysis was performed on patients with node-positive breast cancer, who were enrolled in the ALTTO phase III adjuvant trial and subjected to BCS. The primary objective of the present study was to examine the effect of RNI on disease-free survival (DFS). Secondary objectives included regional recurrences and overall survival (OS). A multivariate cox regression analysis adjusted for number of positive lymph nodes, tumor size, grade, age, hormone receptors status, presence of macrometastatis, treatment arm, and chemotherapy timing was carried out to interrogate the relation between RNI and DFS. Results: 1,664 HER2-positive breast cancer patients were included, of whom 878 patients (53%) had received RNI to the axillary, supraclavicular and/or internal mammary lymph nodes. Patients in the RNI group had higher nodal burden (55% vs 13% patients with ≥ 4 positive lymph nodes) and more frequently tumors larger than 2cm (53% vs 44%). At a median follow-up of 4.5 years, DFS was 84% in the RNI group and 88% in the non-RNI group. No differences in regional recurrence (1% vs 1%) and in OS (94% vs 95%) were observed between the two groups. In the multivariate analysis, there was no significant association between RNI and DFS (HR 0.96, 95% CI 0.71-1.29). Conclusions: Our analysis did not demonstrate a DFS benefit of RNI in HER2-positive, node positive patients treated with adjuvant HER2-targeted therapy. The benefit of RNI in HER2-positive breast cancer needs further testing within randomized clinical trials.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 604
Regional nodal irradiation after breast conserving surgery for HER2-positive breast cancer: Results of a sub analysis from the ALTTO trial.
604 Background: The optimal treatment of regional nodal areas following breast-conserving surgery (BCS) is a source of debate. Two randomized trials recently demonstrated that regional nodal irradiation (RNI) can reduce the risk of recurrence in early breast cancer; however,these trials were conducted in the pre-trastuzumab era.Whether these results are applicable to HER2-positive breast cancer patients treated with anti-HER2 targeted therapy, is unknown. Methods: This retrospective analysis was performed on patients with node-positive breast cancer, who were enrolled in the ALTTO phase III adjuvant trial and subjected to BCS. The primary objective of the present study was to examine the effect of RNI on disease-free survival (DFS). Secondary objectives included regional recurrences and overall survival (OS). A multivariate cox regression analysis adjusted for number of positive lymph nodes, tumor size, grade, age, hormone receptors status, presence of macrometastatis, treatment arm, and chemotherapy timing was carried out to interrogate the relation between RNI and DFS. Results: 1,664 HER2-positive breast cancer patients were included, of whom 878 patients (53%) had received RNI to the axillary, supraclavicular and/or internal mammary lymph nodes. Patients in the RNI group had higher nodal burden (55% vs 13% patients with ≥ 4 positive lymph nodes) and more frequently tumors larger than 2cm (53% vs 44%). At a median follow-up of 4.5 years, DFS was 84% in the RNI group and 88% in the non-RNI group. No differences in regional recurrence (1% vs 1%) and in OS (94% vs 95%) were observed between the two groups. In the multivariate analysis, there was no significant association between RNI and DFS (HR 0.96, 95% CI 0.71-1.29). Conclusions: Our analysis did not demonstrate a DFS benefit of RNI in HER2-positive, node positive patients treated with adjuvant HER2-targeted therapy. The benefit of RNI in HER2-positive breast cancer needs further testing within randomized clinical trials.
- 1 February 2016
- Published by Elsevier in European Journal of Cancer
- Vol. 54, 165-166
Response to ‘Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?’
- 1 February 2016
- Published by Elsevier in European Journal of Cancer
- Vol. 54, 165-166
Response to ‘Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?’
- Open Access
- 15 October 2015
- Published by Springer Nature in BMC Medicine
- Vol. 13 (1) , 1-7
Genomic aberrations in young and elderly breast cancer patients
Age at breast cancer diagnosis is a known prognostic factor. Previously, several groups including ours have shown that young age at diagnosis is associated with higher prevalence of basal-like tumors and aggressive tumor phenotypes. Yet the impact of age at diagnosis on the genomic landscape of breast cancer remains unclear. In this study, we examined the pattern of somatic mutations, chromosomal copy number variations (CNVs) and transcriptomic profiles in young and elderly breast cancer patients. Analyses were performed on The Cancer Genome Atlas (TCGA) dataset. Patients with metastatic disease at diagnosis, classified as normal-like by PAM50 or had missing clinical information were excluded. Young patients were defined as ≤45 years of age, while elderly patients were those ≥70 years of age at breast cancer diagnosis. The remaining patients were classified as “intermediate”. We evaluated the association between age at diagnosis and somatic mutations, CNV and gene expression in a logistic regression model adjusting for tumor size, nodal status, histology and breast cancer subtype. All analyses were corrected for multiple testing using the Benjamini–Hochberg approach. In this study, 125, 486 and 169 patients were ≤45, 46–69 and ≥70 years of age, respectively. Older patients had more somatic mutations (n = 44 versus 35 versus 31; P = 0.0009) and more CNVs, especially in ductal tumors (P = 0.02). Eleven mutations were independently associated with age at diagnosis, of which only GATA3 was associated with young age (15.2 % versus 8.2 % versus 9 %; P = 0.003). Only two CNV events were independently associated with age, with more chr18p losses in older patients and more chr6q27 deletions in younger ones. Younger age at diagnosis was associated with higher expression of gene signatures related to proliferation, stem cell features and endocrine resistance. Age adds a layer of biological complexity beyond breast cancer molecular subtypes, classic pathological and clinical variables, worthy of further consideration in future drug development as we seek to refine therapeutic strategies in the era of personalized medicine.
- 15 October 2015
- Published by Springer Nature in BMC Medicine
- Vol. 13 (1) , 1-7
Open AccessGenomic aberrations in young and elderly breast cancer patients
Age at breast cancer diagnosis is a known prognostic factor. Previously, several groups including ours have shown that young age at diagnosis is associated with higher prevalence of basal-like tumors and aggressive tumor phenotypes. Yet the impact of age at diagnosis on the genomic landscape of breast cancer remains unclear. In this study, we examined the pattern of somatic mutations, chromosomal copy number variations (CNVs) and transcriptomic profiles in young and elderly breast cancer patients. Analyses were performed on The Cancer Genome Atlas (TCGA) dataset. Patients with metastatic disease at diagnosis, classified as normal-like by PAM50 or had missing clinical information were excluded. Young patients were defined as ≤45 years of age, while elderly patients were those ≥70 years of age at breast cancer diagnosis. The remaining patients were classified as “intermediate”. We evaluated the association between age at diagnosis and somatic mutations, CNV and gene expression in a logistic regression model adjusting for tumor size, nodal status, histology and breast cancer subtype. All analyses were corrected for multiple testing using the Benjamini–Hochberg approach. In this study, 125, 486 and 169 patients were ≤45, 46–69 and ≥70 years of age, respectively. Older patients had more somatic mutations (n = 44 versus 35 versus 31; P = 0.0009) and more CNVs, especially in ductal tumors (P = 0.02). Eleven mutations were independently associated with age at diagnosis, of which only GATA3 was associated with young age (15.2 % versus 8.2 % versus 9 %; P = 0.003). Only two CNV events were independently associated with age, with more chr18p losses in older patients and more chr6q27 deletions in younger ones. Younger age at diagnosis was associated with higher expression of gene signatures related to proliferation, stem cell features and endocrine resistance. Age adds a layer of biological complexity beyond breast cancer molecular subtypes, classic pathological and clinical variables, worthy of further consideration in future drug development as we seek to refine therapeutic strategies in the era of personalized medicine.
- 1 August 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51 (12) , 1490-1496
Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome
- 1 August 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51 (12) , 1490-1496
Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome
- 1 June 2015
- Vol. 13 (6) , 372-82
Immunology and breast cancer: toward a new way of understanding breast cancer and developing novel therapeutic strategies.
Every cancer triggers an immune response that constitutes an important first-line protection against cancer progression. In breast cancer, there is an increasing awareness of the relationship between the immune system and tumor evolution. The tumor microenvironment is composed of a variety of immune cells that can control or arrest malignant progression. Chemotherapy and targeted therapy have been shown to modulate this immune microenvironment. Recently, tumor-infiltrating lymphocytes have emerged as a predictive and prognostic biomarker in early breast cancer. In addition, immune gene expression signatures have been shown to be associated with prognosis in triple-negative and human epidermal growth factor receptor 2-positive breast cancer. Such findings have increased interest in the development of immunotherapeutic agents for breast cancer, and multiple clinical trials of anticancer vaccines and immune checkpoint inhibitors are ongoing. In this review, we summarize what is known about the relationship between immunity and breast carcinoma, explore the relevance of this information to the clinical and research settings, and give a portrait of new therapeutic strategies using immunotherapy in breast cancer.
- 1 June 2015
- Vol. 13 (6) , 372-82
Immunology and breast cancer: toward a new way of understanding breast cancer and developing novel therapeutic strategies.
Every cancer triggers an immune response that constitutes an important first-line protection against cancer progression. In breast cancer, there is an increasing awareness of the relationship between the immune system and tumor evolution. The tumor microenvironment is composed of a variety of immune cells that can control or arrest malignant progression. Chemotherapy and targeted therapy have been shown to modulate this immune microenvironment. Recently, tumor-infiltrating lymphocytes have emerged as a predictive and prognostic biomarker in early breast cancer. In addition, immune gene expression signatures have been shown to be associated with prognosis in triple-negative and human epidermal growth factor receptor 2-positive breast cancer. Such findings have increased interest in the development of immunotherapeutic agents for breast cancer, and multiple clinical trials of anticancer vaccines and immune checkpoint inhibitors are ongoing. In this review, we summarize what is known about the relationship between immunity and breast carcinoma, explore the relevance of this information to the clinical and research settings, and give a portrait of new therapeutic strategies using immunotherapy in breast cancer.
- 1 June 2015
- Published by Elsevier in The Breast
- Vol. 24 (3) , 290-293
Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy
- 1 June 2015
- Published by Elsevier in The Breast
- Vol. 24 (3) , 290-293
Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy
- 29 May 2015
- Published by Elsevier
- Vol. 26 (8) , 1521-1523
Has the time come for genomic tests to guide the use of adjuvant chemotherapy in node-positive breast cancer?
- 29 May 2015
- Published by Elsevier
- Vol. 26 (8) , 1521-1523
Has the time come for genomic tests to guide the use of adjuvant chemotherapy in node-positive breast cancer?
- 21 April 2015
- Published by Elsevier
- Vol. 26 (7) , 1511
Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patients
Gnant et al. presented the final results of the Austrian Breast and Colorectal Cancer Study Group Trial 12 (ABCSG-12) trial after a median follow-up of 94.4 months [1]. Although there was no disease free survival (DFS) difference between patients who received ovarian function suppression (OFS) plus either tamoxifen or anastrozole, patients treated with anastrozole + OFS had a significantly worse overall survival (OS) compared with patients treated with tamoxifen + OFS (hazard ratio = 1.63; 95% confidence interval 1.05–1.45; P = 0.030). These results contradict the results of the combined analysis of SOFT/TEXT trials which showed that 5 years of an aromatase inhibitor (AI) + OFS was associated with a superior DFS when compared with 5 years of tamoxifen + OFS and similar OS. Moreover, these results also contradict the results of numerous trials in the postmenopausal setting that have consistently shown a clear superiority of AI over tamoxifen in DFS and in some trials even an OS benefit [2].
- 21 April 2015
- Published by Elsevier
- Vol. 26 (7) , 1511
Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patients
Gnant et al. presented the final results of the Austrian Breast and Colorectal Cancer Study Group Trial 12 (ABCSG-12) trial after a median follow-up of 94.4 months [1]. Although there was no disease free survival (DFS) difference between patients who received ovarian function suppression (OFS) plus either tamoxifen or anastrozole, patients treated with anastrozole + OFS had a significantly worse overall survival (OS) compared with patients treated with tamoxifen + OFS (hazard ratio = 1.63; 95% confidence interval 1.05–1.45; P = 0.030). These results contradict the results of the combined analysis of SOFT/TEXT trials which showed that 5 years of an aromatase inhibitor (AI) + OFS was associated with a superior DFS when compared with 5 years of tamoxifen + OFS and similar OS. Moreover, these results also contradict the results of numerous trials in the postmenopausal setting that have consistently shown a clear superiority of AI over tamoxifen in DFS and in some trials even an OS benefit [2].
- 1 April 2015
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 41 (4) , 301-309
Targeted agents for cancer treatment during pregnancy
- 1 April 2015
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 41 (4) , 301-309
Targeted agents for cancer treatment during pregnancy
- Open Access
- 21 February 2015
- Published by Springer Nature in Breast Cancer Research
- Vol. 17 (1) , 24
RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy
Introduction: RANKL is important in mammary gland development during pregnancy and mediates the initiation and progression of progesterone-induced breast cancer. No clinical data are available on the effect of pregnancy on RANK/RANKL expression in young breast cancer patients. Methods: We used our previously published dataset of 65 pregnant and 130 matched young breast cancer patients with full clinical, pathological, and survival information. 85% of patients had available transcriptomic data as well. RANK/RANKL expression by immunohistochemistry using H-score on the primary tumor and adjacent normal tissue was performed. We examined the difference in expression of RANK/RANKL between pregnant and non-pregnant patients and their association with clinicopathological features and prognosis. We also evaluated genes and pathways associated with RANK/RANKL expression on primary tumors. Results: RANKL but not RANK expression was more prevalent in the pregnant group, both on the tumor and adjacent normal tissue, independent of other clinicopathological factors (both P P P <0.001). Using false discovery rate <0.05, 151 and 1,207 genes were significantly correlated with tumor-expressed RANKL and RANK expression by immunohistochemistry, respectively. High RANKL expression within primary tumor was associated with pathways related to mammary gland development, bone resorption, T-cell proliferation and regulation of chemotaxis, while RANK expression was associated with immune response and proliferation pathways. At a median follow-up of 65 months, neither RANK nor RANKL expression within tumor was associated with disease free survival in pregnant or non-pregnant group. Conclusions: Pregnancy increases RANKL expression both in normal breast and primary tumors. These results could guide further development of RANKL-targeted therapy.
- 21 February 2015
- Published by Springer Nature in Breast Cancer Research
- Vol. 17 (1) , 24
Open AccessRANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy
Introduction: RANKL is important in mammary gland development during pregnancy and mediates the initiation and progression of progesterone-induced breast cancer. No clinical data are available on the effect of pregnancy on RANK/RANKL expression in young breast cancer patients. Methods: We used our previously published dataset of 65 pregnant and 130 matched young breast cancer patients with full clinical, pathological, and survival information. 85% of patients had available transcriptomic data as well. RANK/RANKL expression by immunohistochemistry using H-score on the primary tumor and adjacent normal tissue was performed. We examined the difference in expression of RANK/RANKL between pregnant and non-pregnant patients and their association with clinicopathological features and prognosis. We also evaluated genes and pathways associated with RANK/RANKL expression on primary tumors. Results: RANKL but not RANK expression was more prevalent in the pregnant group, both on the tumor and adjacent normal tissue, independent of other clinicopathological factors (both P P P <0.001). Using false discovery rate <0.05, 151 and 1,207 genes were significantly correlated with tumor-expressed RANKL and RANK expression by immunohistochemistry, respectively. High RANKL expression within primary tumor was associated with pathways related to mammary gland development, bone resorption, T-cell proliferation and regulation of chemotaxis, while RANK expression was associated with immune response and proliferation pathways. At a median follow-up of 65 months, neither RANK nor RANKL expression within tumor was associated with disease free survival in pregnant or non-pregnant group. Conclusions: Pregnancy increases RANKL expression both in normal breast and primary tumors. These results could guide further development of RANKL-targeted therapy.